476 related articles for article (PubMed ID: 29193012)
21. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract][Full Text] [Related]
22. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger M; Lengerke C; Passweg J
Cancer Genomics Proteomics; 2016 09-10; 13(5):317-29. PubMed ID: 27566651
[TBL] [Abstract][Full Text] [Related]
23. Revisiting maintenance therapy in acute myeloid leukemia with novel agents.
Canaani J; Luger SM
Curr Opin Hematol; 2016 Mar; 23(2):175-80. PubMed ID: 26766539
[TBL] [Abstract][Full Text] [Related]
24. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
25. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
26. What are the most promising new agents in acute myeloid leukemia?
Sallman DA; Lancet JE
Curr Opin Hematol; 2017 Mar; 24(2):99-107. PubMed ID: 28030373
[TBL] [Abstract][Full Text] [Related]
27. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
Grunwald MR; Levis MJ
Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
[TBL] [Abstract][Full Text] [Related]
28. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
29. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission.
Shallis RM; Podoltsev NA
Curr Opin Hematol; 2021 Mar; 28(2):110-121. PubMed ID: 33394722
[TBL] [Abstract][Full Text] [Related]
30.
Naqvi K; Ravandi F
Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
[TBL] [Abstract][Full Text] [Related]
31. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
32. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
33. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
34. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Corbali MO; Eskazan AE
Future Oncol; 2020 May; 16(14):887-889. PubMed ID: 32338053
[No Abstract] [Full Text] [Related]
35. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
[TBL] [Abstract][Full Text] [Related]
36. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
Sami SA; Darwish NHE; Barile ANM; Mousa SA
Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
[TBL] [Abstract][Full Text] [Related]
37. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
38. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C; Portwood SM; Przespolewski A; Wang ES
Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
[TBL] [Abstract][Full Text] [Related]
39. [Acute myeloid leukemia].
Döhner K; Paschka P; Döhner H
Internist (Berl); 2015 Apr; 56(4):354-63. PubMed ID: 25787321
[TBL] [Abstract][Full Text] [Related]
40. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara F
Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
